Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) (ADjoin)
Atopic Dermatitis
About this trial
This is an interventional treatment trial for Atopic Dermatitis focused on measuring Eczema, Dermatitis, Dermatitis, Atopic, Skin Diseases
Eligibility Criteria
Inclusion Criteria for participants coming from a parent study:
Participants must meet all the following criteria to be eligible for this study:
- Received treatment in a lebrikizumab study, NCT04146363, NCT04178967, NCT04250337, NCT04250350 and have adequately completed the study treatments and last patient visit of the parent trial.
- For women of childbearing potential: agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method during the treatment period and for at least 18 weeks after the last dose of lebrikizumab or placebo.
Exclusion Criteria for participants coming from a parent study:
Participants meeting any of the criteria below will not be included in this study:
- Participants who, during their participation in the parent trial, developed a serious adverse event (SAE) deemed related to lebrikizumab, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the participant. *
- Participants who, during their participation in the parent trial, developed an AE that was deemed related to lebrikizumab and led to study treatment discontinuation, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the participant. *
- Conditions in the previous parent study consistent with protocol-defined criteria for permanent study drug discontinuation, if deemed related to lebrikizumab or led to investigator - or sponsor-initiated withdrawal of participant from the study (e.g., non-compliance, inability to complete study assessments, etc.). *
- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.
Open-Label Addendum Inclusion Criteria:
Participants must meet all the following criteria to be eligible for this study addendum:
- Male or female adults and adolescents (≥12 to <18 years of age and weighing ≥40 kilogram (kg).
- Chronic AD (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before screening.
- Eczema Area and Severity Index (EASI) score ≥16 at baseline.
- Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at baseline.
- ≥10% body surface area (BSA) of AD involvement at baseline.
- History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable.
Open-Label Addendum Exclusion Criteria:
Participants meeting any of the criteria below will be excluded from this study addendum:
- Have received a dose of lebrikizumab in any prior lebrikizumab clinical study.
- History of anaphylaxis
- Treatment with topical prescription moisturizers, corticosteroids, calcineurin inhibitors, or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to baseline.
Treatment with any of the following agents within 4 weeks prior to the baseline.
- Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)
- Phototherapy and photochemotherapy (PUVA) for AD.
Treatment with the following prior to baseline:
- Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)
- Phototherapy and photochemotherapy (PUVA) for AD.
Treatment with the following prior to baseline:
- An investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer.
- B Cell-depleting biologics, including rituximab, within 6 months.
- Other Biologics within 5 half-lives (if known) or 8 weeks, whichever is longer.
- Regular use (more than 2 uses per week) of a tanning booth/parlor within 4 weeks of baseline.
- Treatment with a live (attenuated) vaccine within 12 weeks of the baseline or planned during the study.
- Uncontrolled chronic disease that might require multiple intermittent uses of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma, (as defined by the investigator).
- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.
- Evidence of active acute or chronic hepatitis
- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.
- History of malignancy, including mycosis fungoides, within 5 years before screening, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin with no evidence of recurrence in the past 12 weeks.
Sites / Locations
- Pinnacle Research Group, LLC
- Clinical Research Center of Alabama- Birmingham
- Investigate MD
- Johnson Dermatology
- Burke Pharmaceutical Research
- Arkansas Research Trials
- Northwest Arkansas Clinical Trials Center
- Orange County Research Institute
- Bakersfield Dermatology and Skin Cancer Medical Group
- Wallace Medical Group, Inc.
- Hope Clinical Research, Inc.
- California Dermatology & Clinical Research Institute
- First OC Dermatology
- MD Studies
- Center For Dermatology Clinical Research, Inc.
- Axon Clinical Research
- Sunwise Clinical Research
- Avance Trials
- California Allergy and Asthma Medical Group + Research Center
- Keck School of Medicine University of Southern California
- Dermatology Research Associates
- LA Universal Research Center, INC
- Ablon Skin Institute and Research Center
- Dermatology Clinical Trials
- Cura Clinical Research
- Integrative Skin Science and Research
- Integrative Skin Science and Research
- Therapeutics Clinical Research
- University Clinical Trials
- University of California, San Diego/Rady Children's Hospital, San Diego - Pediatric & Adolescent Dermatology
- Synergy Dermatology
- Care Access Research
- San Luis Dermatology & Laser Clinic
- Southern California Dermatology, Inc.
- IMMUNOe International Research Centers
- Asthma and Allergy Associates, PC
- Central Connecticut Dermatology
- Medical Faculty Associates, Inc.
- George Washington University Medical Center
- St. Francis Medical Institute
- Florida Academic Centers Research and Education, LLC
- Pediatric Skin Research, LLC
- Clinical Physiology Associates
- The University of Florida Health System
- Direct Helpers Research Center
- The Community Research of South Florida
- Encore Medical Research
- Solutions Through Advanced Research
- GSI Clinical Research, LLC
- C & R Research Services USA
- Wellness Clinical Research
- Vitae Research Center, LLC
- Acevedo Clinical Research Associates
- International Dermatology Research, Inc.
- Community Research Foundation Inc
- Sanchez Clinical Research Inc
- Miami Dermatology and Laser Research
- Well Pharma Medical Research Corp.
- Florida Research Center, Inc
- Tory Sullivan, MD PA
- Park Avenue Dermatology
- Riverchase Dermatology and Cosmetic Surgery
- ForCare Clinical Research
- University of South Florida College of Medicine
- Georgia Pollens Clinical Research Centers, Inc
- IACT Health - VHC
- Marietta Dermatology Clinical Research
- Advanced Medical Research
- Georgia Skin & Cancer Clinic
- Northwestern University
- Sneeze, Wheeze, & Itch Associates LLC
- Arlington Dermatology
- Dundee Dermatology
- Dawes Fretzin Clinical Research Group, LLC
- The Indiana Clinical Trials Center
- Epiphany Dermatology of Kansas, LLC
- Kansas Medical Clinic, an Elligo Health Research, Inc.
- Kansas Medical Clinic
- Skin Sciences, PLLC
- Meridian Clinical Research
- Tulane Univ School of Med
- Dermatology and Skin Cancer Specialists, LLC
- ActivMed Practices and Research
- Tufts Medical Center
- Brigham and Women's Hospital
- Metro Boston Clinical Partners
- Beacon Clinical Research, LLC
- Fivenson Dermatology
- Oakland Dermatology
- Great Lakes Research Group, Inc.
- Michigan Center for Research Company
- Henry Ford Hospital
- St Joseph Dermatology and Vein Clinic
- Associated Skin Care Specialists
- MediSearch Clinical Trials
- Central Dermatology PC
- Advanced Dermatology of the Midlands
- JDR Dermatology Research
- ALLCUTIS Research
- Psoriasis Treatment Center of Central New Jersey
- Skin Laser and Surgery Specialists, a Division of Schweiger Dermatology
- Forest Hills Dermatology Group
- JUVA Skin & Laser Center
- Icahn Sch of Med at Mt. Sinai
- Sadick Research Group
- Advanced Asthma and Allergy
- OnSite Clinical Solutions
- Medication Management
- Wake Research Associates
- Wilmington Dermatology Center
- University Hospitals Case Medical Center
- Ohio Pediatric Research Association
- Lynn Health Science Institute
- Unity Clinical Research
- Central States Research
- Vital Prospects Clinical Research Institute, PC
- Crisor, LLC, Medford office
- Oregon Dermatology and Research Center
- Oregon Medical Research Center
- OHSU Center for Health and Healing
- The Pennsylvania Centre for Dermatology, LLC
- Paddington Testing Company Inc
- University of Pennsylvania Hospital
- DermDox Dermatology Centers
- Peak Research LLC
- Clinical Partners, LLC
- AAPRI Clinical Research Institute
- Palmetto Clinical Trial Services, LLC
- Clinical Research Center of the Carolinas
- Medical University of South Carolina
- Rivergate Dermatology Clinical Research Center PL
- Arlington Research Center, Inc
- Bellaire Dermatology Associates
- Dermatology Treatment and Research Center
- Modern Research Associates
- Austin Institute for Clinical Research
- Innovate Research, LLC
- Center for Clinical Studies
- Suzanne Bruce and Associates, PA
- Encore Imaging & Medical Research
- Cutis Wellness Dermatology
- Laredo Dermatology Associates P.A.
- Austin Institute for Clinical Research
- Progressive Clinical Research
- Texas Dermatology and Laser Specialists
- Acclaim Dermatology PLLC
- Center for Clinical Studies
- University of Utah MidValley Dematology
- Velocity Clinical Research - Woseth Dermatology
- Jordan Valley Dermatology Center
- PI-Coor Clinical Research, LLC
- Virginia Clinical Research, Inc.
- Dermatology Associates of Seattle
- Premier Clinical Research
- Woden Dermatology
- The Skin Hospital
- Premier Specialists Pty Ltd
- The St. George Hospital
- Holdsworth House Medical Practice
- Skin & Cancer Foundation Australia
- Westmead Hospital
- The Skin Centre
- University of the Sunshine Coast Clinical Trial Centre
- Veracity Clinical Research Pty Ltd
- Clinical Trials SA Pty Ltd
- Emeritus Research
- Skin Health Institute Inc.
- Sinclair Dermatology
- The Royal Melbourne Hospital
- Royal Children's Hospital
- Fremantle Dermatology
- Burswood Dermatology
- Captain Stirling Medical Centre
- DCC Sveti Georgi
- Diagnostic and Consultation Center 14
- Alexandrovska University Hospital
- Euro Derma clinic
- Military Medical Academy
- Medical centre Alitera-Med EOOD
- Dermatology Research Institute
- CARe Clinic
- Dr. Chih-ho Hong Medical Inc.
- Enverus Medical Research
- University of British Columbia
- Wiseman Dermatology Research Inc.
- CCA Medical Research
- Simcoderm Medical & Surgical Dermatology Centre
- Skin Health
- Lynderm Research Inc.
- North York Research Inc.
- The Centre for Clinical Trials, Inc
- Ottawa Allergy Research Corp
- Dermatology Ottawa Research Centre
- The Centre for Dermatology
- AvantDerm
- K. Papp Clinical Research
- International Dermatology Research
- Vahlberg & Pild OU
- Kliiniliste uuringute Keskus OU
- Tartu University Hospital
- CHU de Bordeaux Hop St ANDRE
- CHRU de Brest - Hôpital Morvan
- CHU Dijonon
- CHD Vendee
- Cabinet Médical
- Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
- CHU de Nice Hopital de L'Archet
- Hopital Saint Louis
- Hopital Larrey
- Studienzentrum Dr.Beate Schwarz
- Hautarztpraxis am Löwenmarkt
- Dermazentrum Augsburg
- Rosenpark Research GmbH
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
- Klinische Forschung Osnabrück
- Fachklinik Bad Bentheim
- Elbe Klinikum Buxtehude
- Hautzentrum im Jahrhunderthaus
- Company for Medical Study & Service Selters GmbH
- Hautarztpraxis Dr. Gerlach
- Universität Leipzig - Universitätsklinikum
- Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus - Klinik und Poliklinik fuer
- Velocity Clinical Research Leipzig GmbH
- SRH Wald-Klinikum Gera
- Praxis Dr. med. Virgil-Oreste Mihaescu Facharzt fr Dermatologie und STD
- Charité Campus Virchow-Klinikum
- ISA GmbH
- Praxis für Ganzheitliche Dermatologie im Ärztehaus
- Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus - Klinik und Poliklinik fuer
- Dermatologikum Hamburg
- TFS Trial Support Form GmbH
- Soon Chun Hyang University Bucheon Hospital
- Ajou University Hospital
- Pusan National University Hospital
- Hanyang University Medical Center
- Asan Medical Center
- Korea University Ansan Hospital
- Incheon St. Mary's Hospital
- Severance Hospital, Yonsei University Health System
- Konkuk University Medical Center
- Clinic of Dermatology and STD
- Health and Aesthetics LTD
- Latvian Dermatology Institute
- Health Center 4, Affiliate Diagnostic Center
- Smite Aija - Doctor Practice in Dermatology Venereology
- JSC "CD8 Alergology Clinic"
- Hospital of Lithuanian University of Health Sciences Kauno klinikos
- Jsc Renmeda
- JSC "Center for Diagnosis and Treatment of Allergic Diseases"
- JSC Inlita (Santaros CTC)
- Vilnius University Hospital Santaros Klinikos
- Hospital Infantil de Mexico Federico Gomez
- Grupo Clinico CATEI Sociedad Civil
- Clinica De Enfermedades Cronicas y Procedimientos Especiales
- Cemdeicy S.C.P.
- Derma Norte del Bajio
- Arke Estudios Clinicos S.A. de C.V.
- dermMedica Sp. z o.o.
- Dermoklinika Centrum Medyczne s.c. M. Kierstan J. Narbutt A. Lesiak
- Grazyna Pulka Specjalistyczny Osrodek "ALL-MED"
- Diamond Clinic
- Centrum Medyczne Evimed
- Centralny Szpital Kliniczny MSWiA
- Labderm s.c.
- Clinica Vitae Sp. z o.o.
- Zespol Naukowo - Leczniczy "Iwolang" Sp. z o.o.
- Laser Clinic Dermatologia Laserowa Medycyna Estetyczna
- Prywatna Praktyka Lekarska Gabinet Pediatryczno-Alergologiczny Anna Ploszczuk
- Wojewodzki Szpital Zespolony
- Oddzial Dermatologii COPERNICUS
- Holsamed
- Gabinet Dermatlogiczny. Beata Krecisz
- Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie
- Centrum Alergologii Teresa Hofman
- Kliniczny Szpital Wojewodzki nr. 1 Klinika Dermatologii
- Twoja Przychodnia - Szczecinskie Centrum Medyczne
- Alergo-Med Specjalistyczna Przychodnia Lekarska Sp Z O.O.
- Clinical Research Group Sp. z o.o.
- High-Med Prywatny Gabinet Lekarski
- MTZ Clinical Research Sp.z.o.o.
- Klinika Ambroziak Sp. Z.O.O.
- CityClinic Przychodnia Lekarsko-Psychologiczna
- Centrum Medyczne Angelius Provita
- National University Hospital
- Singapore General Hospital
- Kk Women'S and Childrens Hospital
- National Skin Centre NSC
- Hospital Sant Joan de Déu
- Hospital Germans Trias i Pujol
- Hospital General Universitario de Alicante
- Hospital Clinic de Barcelona
- Hospital de la Santa Creu i Sant Pau
- Hospital Universitario Basurto
- Hospital Universitario Infanta Leonor-INTERNAL MED
- Hospital Universitario Virgen Macarena
- Kaohsiung Chang Gung Memorial Hospital
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Taipei Medical University Shuang Ho Hospital
- Chung Shan Medical University Hospital
- China Medical University Hospital
- National Taiwan University Hospital
- Community Institution Zaporizhzhya Regional Dermatovenereology Clinical Hospital of Zaporizhzhya Regional Council
- Municipal Healthcare Institution Kharkiv City Dermatoverenologic Dispensary N2
- SE "Institute of Dermatology and Venerology of NAMS of Ukraine"
- Rivne Regional Dermatology and Venereology Dispensary
- Treatment-diagnostic center PE "Asclepius"
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Lebrikizumab Q2W (Open-Label) from Parent Study
Lebrikizumab Q2W (Blinded) from Parent Study
Lebrikizumab Q2W (Open-Label Addendum)
Lebrikizumab Q4W
Participants assigned to lebrikizumab Q2W (once every 2 weeks) arm will receive investigational product Q2W by subcutaneous (SC) injection.
Participants assigned to lebrikizumab Q2W arm will receive investigational product Q2W by SC injection. Some participants will receive loading doses.
Participants enrolling in Open-Label Addendum will receive lebrikizumab Q2W by SC injection after loading doses.
Participants assigned to lebrikizumab Q4W (once every 4 weeks) arm will receive investigational product Q4W by SC injection. Intervention assigned: Lebrikizumab balanced with Placebo to maintain the blind between treatment arms.